Bioventus (BVS) Total Non-Current Liabilities (2020 - 2026)

Bioventus (BVS) has 7 years of Total Non-Current Liabilities data on file, last reported at $402.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 16.94% year-over-year to $402.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $402.0 million (down 16.94% YoY) and the FY2025 annual result came in at $439.8 million, down 15.31% from the prior year.
• Total Non-Current Liabilities eased to $402.0 million in Q1 2026, from $439.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $994.6 million in Q4 2022 to a low of $402.0 million in Q1 2026.
• A 5-year average of $596.1 million and a median of $561.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 147.58% — and 2023, when it plunged 44.33%.
• Tracing BVS's Total Non-Current Liabilities over 5 years: stood at $943.0 million in 2022, then plunged by 40.42% to $561.9 million in 2023, then dropped by 7.58% to $519.2 million in 2024, then dropped by 15.31% to $439.8 million in 2025, then declined by 8.59% to $402.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $402.0 million (Q1 2026), $439.8 million (Q4 2025), and $473.9 million (Q3 2025), per Business Quant data.